Evidence map›Paper›PMID 17547719›Full record

ArticleHuman cell2007

Establishment and characterization of an IGSK-2 cell line derived from ascitic fluid of recurrent hCG and somatostatin secreted adenocarcinoma of the stomach.

Satoshi Ohi, Naoto Takahashi, Hisashi Hashimoto, Toshiaki Tachibana, Tetsuya Hirabayashi, Kayoko Sugiyama, Katsuhiko Yanaga, Hiroshi Ishikawa

Abstract read
PubMed Publisher
In one paragraph

Article in Human cell, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Satoshi OhiDepartment of Anatomy II, Jikei University School of Medicine, 3-25-8 Nishi-shinbachi, Minato-ku, Tokyo 105-8461, Japan. satoshi-ohi@jikei.ac.jp
Naoto Takahashi
Hisashi Hashimoto
Toshiaki Tachibana
Tetsuya Hirabayashi
Kayoko Sugiyama
Katsuhiko Yanaga
Hiroshi Ishikawa
Jikei University School of Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We examined a 32-year-old Japanese man who was clinically diagnosed with gastric cancer, type 4, and histopathologically diagnosed with mucinous and poorly differentiated adenocarcinoma (mucinous > poorly) of the stomach. We successfully established and characterized a cell line (designated as IGSK-2) derived from the ascitic fluid of the patient with recurrent and cisplatin-resistant carcinoma. The IGSK-2 cells grew in multi-layered culture in culture dishes. The cells secreted 18 pg/mL somatostatin, 9.1 mIU/mL human chorionic gonadotrophin (hCG), 8000 U/mL carbohydrate antigen 19-9 and 410 ng/mL carcinoembryonic antigen over 4 days of culture. The population doubling time was approximately 83 h. The susceptibility test of anticancer drugs revealed that IGSK-2 cells were sensitive to Taxol, but were not sensitive to cisplatin, 5-fluorouracil and irinotecan. Immunohistochemical staining revealed that the IGSK-2 cells were positive against antihCG antibody and antiserotonin antibody, and negative against antisomatostatin antibody and antigastrin antibody.

Indexed as

Cell Line, TumorAdenocarcinoma, MucinousAdultAnimalsAntigens, Tumor-Associated, CarbohydrateAscitic FluidBiomarkers, TumorCamptothecinCarcinoembryonic AntigenChorionic GonadotropinCisplatinDrug Screening Assays, AntitumorFluorouracilHumansImmunohistochemistryIrinotecanAntigens, Tumor-Associated, CarbohydrateBiomarkers, TumorCamptothecinCarcinoembryonic AntigenChorionic GonadotropinCisplatinFluorouracilIrinotecanPaclitaxelSomatostatin

Identifiers

PMID17547719
OpenAlexW2151448573

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.